Navigation Links
Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
Date:9/30/2008

SAN DIEGO, Sept. 30 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the JMP Securities 3rd Annual Healthcare Focus Conference on Tuesday, October 7, 2008 at 3:00 p.m. EDT (12:00 p.m. PDT). The conference is being held at Le Parker Meridien in New York City.

Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will present an overview of Anadys and its three clinical programs: ANA598 and ANA773 in hepatitis C and ANA773 in cancer.

The presentation will be simultaneously webcast and can be accessed on the Investor Relations page of the Company's website at http://www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to the corporate presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the live webcast concludes and will be available through October 21, 2008.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development prog
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
2. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
3. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
8. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
9. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
10. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
11. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... SALT LAKE CITY , Aug. 28, 2014 /PRNewswire-iReach/ ... in 2000 by service academy graduates, has published a ... its concentrated, three-day Leadership Excellence Course . In ... the  Leadership Excellence Course to Albuquerque , ... Tucson . Photo - http://photos.prnewswire.com/prnh/20140828/140814 ...
(Date:8/28/2014)... 28, 2014 The new ... Market (products, applications, techniques, end users and Geography) ... Forecast, 2013 - 2020," indicates that the global ... 2020 registering a CAGR of 9.8% from 2014 ... and cost effectiveness over alternative diagnostic techniques are ...
(Date:8/28/2014)... Aug. 28, 2014   Venaxis, Inc.  (Nasdaq:  APPY), ... obtaining FDA clearance for and commercializing its CE Marked ... aiding in identifying children, adolescent, and young adult patients ... for appendicitis, today announced it will present at three ... Annual Global Investment Conference being held in ...
Breaking Medicine Technology:Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 2DNA Diagnostics Market is Expected to Reach $19 Billion by 2020 - Allied Market Research 3Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3
... 2010 Kensey Nash Corporation (Nasdaq: KNSY ... in November.   Michael Celano, Kensey Nash,s ... the Oppenheimer 21st Annual Healthcare Conference at the Waldorf ... p.m. (ET).  To hear the live webcast of the ...
... (Nasdaq: SLTM ), a global leader in the ... ended September 30, 2010. Revenue for the third quarter was ... as compared to the third quarter 2009 revenue of $17.8 ... by a year-over-year 40% increase in sales of treatment tips ...
Cached Medicine Technology:Solta Medical Reports Third Quarter 2010 Results 2Solta Medical Reports Third Quarter 2010 Results 3Solta Medical Reports Third Quarter 2010 Results 4Solta Medical Reports Third Quarter 2010 Results 5Solta Medical Reports Third Quarter 2010 Results 6Solta Medical Reports Third Quarter 2010 Results 7Solta Medical Reports Third Quarter 2010 Results 8
(Date:8/28/2014)... Solid-head power toothbrushes retain less bacteria compared ... University of Texas Health Science Center at Houston ... study are published in the August issue of ... professor at the UTHealth School of Dentistry, Donna ... were lower in the solid-head toothbrush group than ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... Initial human testing of an investigational vaccine to prevent ... National Institute of Allergy and Infectious Diseases (NIAID), part ... trial will begin initial human testing of a vaccine ... the experimental vaccine,s safety and ability to generate an ... place at the NIH Clinical Center in Bethesda, Maryland. ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
... today announced their plans to expand their online video ... overwhelming success achieved by the website since its inception ... library has been visited by physicians from 64 different ... from repeat visits and the average length of stay ...
... Recent Developments at Major Patenting Authorities WorldwidePHILADELPHIA and LONDON, ... Thomson Reuters today released its 2009 Patent Focus ... Intellectual Asset Management magazine, and published in the ... , this report explores recent activities at each of ...
... SEATTLE, Feb. 17 Cell Therapeutics, Inc. (Nasdaq and ... a press release in Italy in response to information ... CTI,s business operations and financial condition, which was also ... February 17, 2009, the Borsa Italiana has confirmed that ...
... 17 The civil rights movement gained a ... of Representatives voted Feb. 17 to recognize the ... by American Life League Associate group North Dakota ... of The Personhood of Children Act (House Resolution ...
... Consumers who purchased raw milk from the Swiss Villa ... after Feb. 9 are advised to discard it immediately ... Secretary Dennis Wolff said today. Raw milk has not ... a result of the potential contamination, but if people ...
... Shenghuo,Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ("China ... 10, 2009, it received a,deficiency letter from the ... the,"Exchange") stating that the Company was not in ... standards due to the Company,s failure to,hold an ...
Cached Medicine News:Health News:Physicians online library is a worldwide hit 2Health News:Physicians online library is a worldwide hit 3Health News:Thomson Reuters Releases 2009 Patent Focus Report 2Health News:Cell Therapeutics to Resume Trading on MTA and NASDAQ 2Health News:North Dakota Personhood Bill Passes State House 51-41 2Health News:Consumer Advisory: Agriculture Department Warns of Tainted Raw Milk Sold By Dauphin County Dairy 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 2Health News:China Shenghuo Receives Notice from NYSE Alternext US Regarding Listing Standards 3
... ROM Elbow Orthosis features aluminum cuffs that ... arm. To ensure proper joint alignment, unique ... and distal adjustments to cuff position. Cuffs ... is necessary for use with contractures.,The hinge ...
... Brace is designed to handle post-op elbow ... The Bledsoe Extender Arm Brace should be ... of the elbow is desired. In most ... be formed, fitted and adjusted in 5 ...
... This controlled stretch ankle support helps reduce ... of motion. It is easy to apply ... its slim design fits easily into shoes. ... the ankle, and provide side-to-side support and stability. ...
... ankle support provides excellent com-pression and ... motion. The anatomically sculpted visco-elastic ... weakened or injured soft tissues under ... to apply - slips on like ...
Medicine Products: